OPEN ACCESS

UNIVERSITY OF DUNDEE

University of Dundee

Control of amino-acid transport coordinates metabolic reprogramming in T cell malignancy

Grzes, Katarzyna M.; Swamy, Mahima; Hukelmann, Jens L.; Emslie, Elizabeth; Sinclair, Linda V.; Cantrell, Doreen

Control of amino-acid transport coordinates metabolic reprogramming in T cell malignancy OPEN

K M Grzes, M Swamy, J L Hukelmann, E Emslie, L V Sinclair, D A Cantrell

Control of amino-acid transport coordinates metabolic reprogramming in T cell malignancy

Katarzyna M. Grzes[1,3], Mahima Swamy[1], Jens L. Hukelmann[2], Elizabeth Emslie[1], Linda V. Sinclair[1], Doreen A. Cantrell[1]

[1]Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, DD1 5EH, United Kingdom; [2]Centre for Gene Regulation and Expression, School of Life Sciences, University of Dundee, DD1 5EH, United Kingdom; [3]Present Address: Department of Immunometabolism, Max Planck Institute of Immunology and Epigenetics, 79108 Freiburg, Germany;

Correspondence should be addressed to D. A. Cantrell (d.a.cantrell@dundee.ac.uk).

Abstract

This study explores the regulation and importance of System L amino acid transport in a murine model of T cell acute lymphoblastic leukemia (T-ALL) caused by deletion of phosphatase and tensin homologue deleted on chromosome 10 (PTEN). There has been a strong focus on glucose transport in leukemias but the present data show that primary T-ALL cells have increased transport of multiple nutrients. Specifically, increased leucine transport in T-ALL fuels mammalian target of rapamycin complex 1 (mTORC1) activity which then sustains expression of hypoxia inducible factor-1α (HIF1α) and c-Myc; drivers of glucose metabolism in T cells. A key finding is that PTEN deletion and phosphatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)P$_3$) accumulation is insufficient to initiate leucine uptake, mTORC1 activity, HIF1α or c-Myc expression in T cells and hence cannot drive T-ALL metabolic reprogramming. Instead, a key regulator for leucine transport in T-ALL is identified as NOTCH. Mass spectrometry based proteomics identifies SLC7A5 as the predominant amino acid transporter in primary PTEN$^{-/-}$ T-ALL cells. Importantly, expression of SLC7A5 is critical for the malignant transformation induced by PTEN deletion. These data reveal the importance of regulated amino acid transport for T cell malignancies, highlighting how a single amino acid transporter can play a key role.

2

Introduction

The proliferation of normal and malignant T lymphocytes is supported by signaling pathways that increase nutrient uptake to meet cellular metabolic demands. Immune activated normal T cells and malignant T cells thus increase glucose uptake and switch to glycolysis to use glucose as a carbon source for their increased biosynthetic demands (1-7). In normal T cells, glucose metabolism is controlled by c-Myc and HIF1 transcription factors which regulate expression of genes encoding glucose transporters and glycolytic enzymes (4,8). The serine/threonine kinase mTORC1 also selectively coordinates glucose transport and glycolysis by controlling the expression of HIF1α (4,9). One important question is whether the metabolic reprogramming of transformed T cells replicates the metabolic reprograming of normal proliferating T cells? In this respect, T-ALL are aggressive tumors of T cell progenitors caused by mutations in NOTCH pathway (10) or mutations/loss of expression of PTEN, a lipid phosphatase with specificity for the 3′ position of PtdIns(3,4,5)P$_3$ (11,12). T-ALL have high glucose metabolism (5-7) and c-Myc (13-15), mTORC1 (16-18) and HIF1α (19,20) are important for their development. However, in contrast to normal T cells, it is not known if there is an mTORC1/HIF regulatory circuit in T-ALL.

One mechanism that coordinates c-Myc and mTORC1 signaling in normal T cells is the control of amino acid uptake (21). mTORC1 activity requires sustained leucine and glutamine transport (22). Moreover, c-Myc protein has a very short half-life and can only accumulate in T cells exhibiting high levels of amino acid uptake and protein synthesis (23). The regulated supply of large neutral amino acids (LNAA) mediated by the System L amino acid transporter SLC7A5 (also known as LAT1) is particularly important in T cells for mTORC1 activity and c-Myc expression (21). What about amino acid transport in malignant T cells? Human and mouse malignant T cells express CD98 (SLC3A2) (24,25), one subunit of the System L amino acid transporter complex. T-ALL also express *Slc7a5* mRNA and

3

there is evidence that pharmacological blockade of System L transport suppresses leukemia growth (26). However there has been no direct analysis of the amino acid transport capacity in primary T-ALL. Accordingly, the present study explores amino acid transport in a mouse model of T cell leukemia/lymphoma where thymic deletion of the inositol phosphatase PTEN drives rapid T leukemogenesis/lymphomagenesis (25,27,28). We show that PTEN-null malignant T cells have high membrane transport capacity for multiple nutrients including high System L amino acid transporter activity driven by NOTCH signaling pathways. Moreover, amino acid supply via System L amino acid transporters underpins metabolic reprogramming controlled by mTORC1, c-Myc and HIF1α in malignant T cells and is critical for the *in vivo* malignant transformation induced by PTEN deletion.

4

Methods

Mice

Mice were maintained in the University of Dundee in compliance with UK Home Office Animals (Scientific Procedures) Act 1986. C57BL/6 *Pten*^{fl/fl}*Lck*-Cre, *Hif1a*^{fl/fl}*Lck*-Cre, *Pten*^{fl/fl}*Hif1a*^{fl/fl}*Lck*-Cre and *Pten*^{fl/fl}*Slc7a5*^{fl/fl}*Lck*-Cre mice were bred and genotyped as described in supplemental methods. Experiments were performed using mice between 4 and 6 weeks of age when studying non-transformed PTEN^{-/-} T cells, to ensure the absence of transformed T cells.

Cell cultures and Flow cytometry

F014 and F15 murine PTEN^{-/-} T-ALL cells (29), primary murine cytotoxic T cells (30), OP9-DL-1 and control OP9 bone marrow stromal cells (31) were maintained as described previously. Standard flow cytometric protocols were used to monitor surface antigens and intracellular S6 phosphorylated on Ser235 and Ser236 (32). Details of antibodies used are in supplemental methods. Data were acquired on LSR Fortessa or FACSVerse machines (Becton Dickinson) and analyzed using FlowJo software (TreeStar).

Nutrient uptakes

Glucose, glutamine and leucine transport were measured using [^{3}H]-2-deoxyglucose (1 µCi ml^{-1}), [^{3}H]-L-glutamine/[^{14}C]-L-glutamine or [^{3}H]-L-leucine as described previously (21). APC-transferrin uptakes were performed as described previously (23).

Protein detection and mRNA quantitation

Immunoblotting for protein expression and phosphorylation and label free quantitative mass spectrometry protocols for protein quantification were as described in (9) and detailed protocols and details of antibodies used are in supplemental methods. Details of mRNA purification and protocols for quantitation by PCR are in supplemental methods.

Statistical analyses

Data sets were analyzed using SigmaPlot 12.5 (Systat) or Prism 6.0 (GraphPad). A Shapiro-Wilk test for normality was performed to determine suitable tests for parametric or non-parametric populations. F-tests were performed to determine equal variance of populations, otherwise tests assuming unequal variance were performed. All utilized tests were two-tailed

5

and are stated in the respective figure legends. Multiple comparisons in one-way ANOVA analyses were corrected for using the Holm-Sidak method. Kaplan-Meier survival analyses were performed for the *Pten*^{fl/fl}*Lck*-Cre, *Pten*^{fl/fl}*Hif1α*^{fl/fl}*Lck*-Cre and *Pten*^{fl/fl}*Slc7a5*^{fl/fl}*Lck*-Cre tumor model.

Results

Increased transport of leucine and multiple nutrients in primary PTEN[-/-] T-ALL cells

Mice with PTEN alleles floxed by loxP Cre excision sequences were backcrossed to *Lck*-Cre transgenic mice that express Cre recombinase selectively in thymic T cell progenitors. *Pten*[fl/fl]*Lck*-Cre[+] mice serve as a murine model of T-ALL as mice develop aggressive T cell lymphomas in the thymus that are fatal at approximately 8-12 weeks (25,28). Primary *ex vivo* PTEN[-/-] T-ALL cells can be isolated from *Pten*[fl/fl]*Lck*-Cre[+] mice for analysis of nutrient transport. **Figure 1a** shows high rates of glucose and glutamine uptake, respectively, in primary *ex vivo* T-ALL cells isolated from *Pten*[fl/fl]*Lck*-Cre[+] mice compared to the nutrient uptake of wild-type thymocytes. Primary PTEN[-/-] T-ALLs also expressed CD71, the transferrin receptor and had high rates of transferrin uptake compared to wild-type thymocytes **(Fig.1b)**. Moreover, PTEN[-/-] T-ALL cells expressed high levels of CD98, a subunit of System L amino acid transporters. They also had increased uptake of the large neutral amino acid (LNAA) leucine compared to wild-type thymocytes. This was comparable to leucine transport levels of CTL (cytotoxic T cells) **(Fig.1c)** used as a positive control due to their high rates of amino acid transport (3,4,21,23). Two murine PTEN[-/-] T-ALL cell lines derived from *Pten*[fl/fl]*Lck*-Cre[+] mice, F04 and F15 (29), also showed constitutively high transport of multiple nutrients including glucose, glutamine, transferrin and leucine as well as high expression of CD71 and CD98 **(Suppl.Fig.1)**.

Nutrient transport in T-ALL is not directly driven by PtdIns(3,4,5)P$_3$ or AKT

In many cells, signaling pathways mediated by PtdIns(3,4,5)P$_3$ and the serine/threonine kinase AKT control nutrient transport (33). However, in normal effector T cells the regulation of nutrient uptake is phosphatidyl-3 kinase (PI3K)/AKT independent (3,4). The *Pten*[fl/fl]*Lck*-Cre[+] mouse model allows the isolation of PTEN[-/-] non-transformed thymocytes

from young (4-6 week old) mice (34). These PTEN$^{-/-}$ non-transformed thymocytes have been well characterized (25,34) and are known to be polyclonal and lack the secondary mutations associated with T-ALL. They had high levels of active AKT and increased phosphorylation of the AKT substrate PRAS40 T246 **(Fig.2a)**. The analysis of nutrient uptake in PTEN$^{-/-}$ non-transformed thymocytes allows an assessment of the ability of PtdIns(3,4,5)P$_3$ and AKT to drive nutrient transport in T cells. The data show that PTEN$^{-/-}$ non-transformed thymocytes did not increase glucose or glutamine transport **(Fig.2b)** nor did they express CD71 or increase transferrin uptake **(Fig.2c)**. PTEN$^{-/-}$ non-transformed thymocytes also had very low CD98 expression and leucine transport **(Fig.2d)**. The failure to see increased nutrient transport in PTEN$^{-/-}$ non-transformed thymocytes shows that AKT activation is insufficient for these processes. Thus, the changes in nutrient transport in PTEN$^{-/-}$ T-ALL must be a consequence of the secondary mutations that drive malignant transformation in these cells (35,36).

Expression of c-Myc, HIF1α and mTORC1 activity in PTEN$^{-/-}$ T-ALL

Increases in glucose, glutamine and transferrin uptake in immune activated normal T cells are regulated by c-Myc and mTORC1, the latter via control of expression of HIF1 complexes (4,8,23). High levels of c-Myc expression are characteristic of T-ALL either as a result of *c-Myc* translocations or NOTCH signaling (14,15,37,38). Hence, wild-type and PTEN$^{-/-}$ non-transformed thymocytes had no detectable expression of c-Myc **(Fig.3a)** and NOTCH1 (**Suppl.Fig.2a**), whereas c-Myc protein was readily observed in primary PTEN$^{-/-}$ T-ALL cells **(Fig.3a)**. What about mTORC1 activity and HIF1α expression in primary PTEN$^{-/-}$ T-ALL cells? Initially we probed mTORC1 activity by analyzing the phosphorylation of p70S6 kinase 1 (S6K). **Figure 3b** shows high levels of S6K phosphorylation on T389, the mTORC1 substrate site, in primary *ex vivo* isolated PTEN$^{-/-}$ T-ALL cells. This S6K T389

8

phosphorylation was lost when cells were treated with the mTORC1 inhibitor, rapamycin. We also assessed mTORC1 activity in PTEN$^{-/-}$ T-ALL cells by quantifying levels of enzymes that control lipid biosynthesis. Their expression is known to be controlled via mTORC1 regulation of the activity of sterol regulatory element binding proteins (SREBPs) (39). This analysis revealed upregulation of SREBP regulated signaling pathways in PTEN$^{-/-}$ T-ALL cells compared with wild-type thymocytes (**Fig.3c**). We then analyzed the expression of HIF1α and found that *ex vivo* isolated PTEN$^{-/-}$ T-ALL cells expressed HIF1α which was in stark contrast to wild-type thymocytes where no HIF1α was detected (**Fig.3d, Suppl.Fig.2b**). Hypoxia promotes the accumulation of HIF1α (40): levels of HIF1α in *ex vivo* PTEN$^{-/-}$ T-ALL PTEN$^{-/-}$ T-ALL cells declined in normoxia (21% O$_2$) but were increased by hypoxia (1% O$_2$) (**Fig.3d**). In contrast, *ex vivo* isolated wild-type and PTEN$^{-/-}$ non-transformed thymocytes did not have high mTORC1 activity (**Fig.3b**), nor did they express detectable HIF1α or increase HIF1α expression under in hypoxia (**Suppl.Fig.2b,c**) although they did express HIF1β (**Suppl.Fig.2d**).

To address if HIF1α expression in T-ALL cells is controlled by mTORC1 we switched to experiments with PTEN$^{-/-}$ T-ALL cell lines (29). **Figure 3e** shows that the murine PTEN$^{-/-}$ T-ALL cell lines, F04 and F15, had high levels of mTORC1 activity as judged by the rapamycin sensitive phosphorylation of S6K T389 and expressed HIF1α under hypoxia and normoxia (**Fig. 3f**). Inhibition of mTORC1 with rapamycin, resulted in a strong decrease in HIF1α expression (**Fig.3g**). Inhibition of mTORC1 in the T-ALL cells also caused a decrease in expression of c-Myc (**Fig.3h**). Furthermore, mTORC1 activity was also required to sustain glucose uptake in PTEN$^{-/-}$ T-ALL cells (**Fig. 3i**).

How important is the ability of mTORC1 to control HIF1α expression in PTEN$^{-/-}$ T-ALL cells? In this context, selective deletion of mTORC1 activity in T cell progenitors extends mouse lifespan in models leukaemogenesis induced by PTEN deletion (18); although cells

9

that have genetically disrupted mTORC1 signaling eventually develop T cell tumors. *Hif1α*^{fl/fl} *Lck*-Cre⁺ mice had normal numbers and frequencies of thymocyte subsets, indicating that deletion of HIF1α in T cell progenitors in the thymus does not impair normal T cell development **(Fig.3j)**. *Pten*^{fl/fl}*Lck*-Cre⁺ mice had a median survival of 68 days and only a small percentage of these mice (14%) survived beyond 100 days. In contrast, *Pten*^{fl/fl}*Hif1α*^{fl/fl} *Lck*-Cre⁺ mice showed prolonged survival with a median life span of 127 days, although they eventually developed PTEN^{-/-} x HIF1α^{-/-} T cell tumors **(Fig.3k)** that had high rates of glucose transport **(Fig.3l, Suppl.Fig.3)**. HIF1α is thus important although not essential for T lymphomagenesis caused by PTEN deletion and HIF1α independent signaling pathways can control glucose transport in T-ALL.

T-ALL and System L amino acid transport

One striking observation was the low levels of mTORC1 activity in PTEN^{-/-} non-transformed thymocytes compared to the high mTORC1 activity in malignant PTEN^{-/-} T-ALL cells **(Fig.3b)**. PtdIns(3,4,5)P$_3$ accumulation and AKT activation **(Fig.2a)** were thus insufficient for mTORC1 activition in thymocytes. One key requirement for mTORC1 activity in PTEN^{-/-} T-ALL cells was the sustained transport of leucine **(Fig.4a)** consistent with the leucine requirement for mTORC1 activity in other cell systems (21,41). Hence, the low mTORC1 activity in PTEN^{-/-} non-transformed thymocytes **(Fig.3b)** was consistent with the absence of leucine transport in these cells **(Fig.2d)**.

What are the leucine transporters in PTEN^{-/-} T-ALL cells? Leucine is preferentially transported by System L amino acid transporters which are heterodimers consisting of CD98 and either SLC7A5 (LAT1), SLC7A8 (LAT2); SLC7A7 (y⁺LAT1) or SLC7A6 (y⁺LAT2) (42). Mass spectrometry proteomic analysis of primary *ex vivo* PTEN^{-/-} T-ALL cells from 3 tumor bearing *Pten*^{fl/fl} *Lck*-Cre⁺ mice identified that these cells expressed CD98, SLC7A5 and

SLC7A6, with SLC7A5 always more abundant than SLC7A6 **(Fig.4b)**. SLC7A5 has a key role in peripheral T cells, controlling mTORC1 activity and c-Myc expression (21), known drivers of T-ALL (13,43). In contrast deletion of *Slc7a5* in T cell progenitors in the thymus does not impair normal T cell development (21). However, SLC7A5 loss dramatically impairs the development of T cell malignancy: *Pten*[fl/fl]*Slc7a5*[fl/fl] *Lck*-Cre[+] mice thus showed prolonged survival (358 days median surivial) compared to the rapid morbidity of *Pten*[fl/fl]*Lck*-Cre[+] mice (68 day median survival) **(Fig.4c)**. Out of 18 *Pten*[fl/fl]*Slc7a5*[fl/fl] *Lck*-Cre[+] mice, only 6 mice developed very late onset PTEN[-/-] x SLC7A5[-/-] T cell tumors **(Suppl.Fig.4)**. SLC7A5 is therefore a dominant System L amino acid transporter in this T-ALL model.

NOTCH1 regulation of leucine uptake in T-ALL

How do T-ALL control SLC7A5 expression and LNAA transport? We have shown that changes in leucine transport in PTEN[-/-] T-ALL cells were not a direct consequence of PTEN deletion or AKT activation as they were not seen in PTEN[-/-] non-transformed thymocytes **(Fig.2b-d)**. We then considered other possible drivers for the changes in leucine transport in T-ALL, and focused on NOTCH. The rationale was that NOTCH activation occurs frequently in human and murine T-ALL (10) and is known to control mTORC1 activity and expression of c-Myc (15,44) and can also drive glucose and glutamine uptake (45).

Initial experiments addressed the role of NOTCH in regulating leucine transport directly in wild-type thymocytes. We used the OP9-DL1 system where OP9 cells expressing the NOTCH ligand delta-like 1 (DL1) support the differentiation and self-renewal of T cell progenitors (46). **Figure 5a** shows that thymocytes maintained in IL-7 on OP9 cells had low levels of leucine transport in contrast to the high levels of leucine uptake in NOTCH-stimulated cells. This leucine uptake was mediated by System L amino acid transporters as

11

evidenced by its sensitivity to the System L competitor BCH **(Fig.5a)**. Leucine uptake was mirrored by the expression of CD98, a subunit of System L amino acid transporter **(Fig.5b)**. Furthermore, only thymocytes that increased leucine uptake showed active mTORC1, as determined by phosphorylation of the S6K substrate, S6 on S235/236 **(Fig.5c)**.

What about the role of NOTCH in established PTEN$^{-/-}$ T-ALL? The T-ALL cell lines F04 and F15 have constitutive NOTCH activity as there is high expression of the NOTCH1 intracellular domain (IC NOTCH1) which is released by NOTCH1 gamma-secretase cleavage between G1743 and V1744 **(Fig.5d)**. The gamma-secretase inhibitor, DAPT, blocked the accumulation of the IC NOTCH1 (V1744) and caused loss of NOTCH transcriptional activity as judged by the loss of expression of c-Myc **(Fig.5d)**. F04 and F15 cells also had high rates of leucine transport that could be partially blocked by NOTCH1 inhibition **(Fig.5e)**. DAPT treated F04 and F15 cells also lost mTORC1 activity, HIF1α expression and glucose transport capacity **(Fig.5d and 5f, respectively)**. NOTCH inhibition in F04 and F15 cells also decreased expression of *Slc7a5* **(Fig.5g)** and *Cd98* **(Fig.5h)**. NOTCH signals thus sustain expression of System L amino acid transporters and LNAA transport in PTEN$^{-/-}$ T-ALL cells.

Discussion

The importance of understanding metabolic checkpoints in malignant cells is now clear. Much work in leukemias has focused on important changes in glucose metabolism but other nutrients such as amino acids and iron are equally important (26,47). The present data highlight how primary PTEN$^{-/-}$ T-ALL cells switch to high rates of transport of multiple nutrients and one discovery is that primary *ex vivo* T-ALL have high System L amono acid transport capacity. Moreover, the regulated transport of LNAA via the amino acid transporter SLC7A5 is key for T cell malignancy. Amino acid transport via System L transporters is important for protein synthesis but also supplies leucine which is essential to sustain mTORC1 activity in T-ALL cells. mTORC1 is able to control T-ALL metabolism by controlling expression of two key transcription factors c-Myc and HIF1α. The importance of c-Myc for T cell leukemia is well established (13). The present data show that HIF1α is also expressed in primary T-ALL cells and is critical for T-ALL development induced by PTEN deletion. In this respect, the impact of HIF1α deletion on the development of the T cell tumors following thymic deletion of PTEN phenocopies the impact of losing mTORC1 activity (18). One role for HIF1α is to regulate the transcription of genes encoding glucose transporters and glycolytic enzymes. It was noteworthy that when *Pten*$^{fl/fl}$*Hif1α*$^{fl/fl}$ *Lck*-Cre$^+$ mice did eventually develop tumors, they had high rates of glucose transport. Therefore, HIF1α independent signaling pathways can mediate glucose metabolism in T-ALL. One alternative regulator is c-Myc which controls the transcription of genes encoding glucose transporters and enzymes controlling glycolysis and glutaminolysis in T cells (8). Another key role for c-Myc is to control glucose flux through the hexosamine biosynthetic pathway which is also essential for the T lymphoma/leukemias driven by PTEN deletion (45). The importance of c-Myc and mTORC1 controlled pathways for malignant T cells would be one reason that an amino acid transporter such as SLC7A5 would also be important. c-Myc

13

expression and mTORC1 activity in T cells are thus highly dependent on the regulated supply of amino acids via System L amino acid transporters (21,23). mTORC1 and c-Myc hence act as signaling hubs that connect amino acid transport to multiple metabolic processes.

Loss and inactivation of PTEN and elevated PtdIns(3,4,5)$_3$ and AKT activity is a common feature of T-ALL malignancy (12). In many cells PtdIns(3,4,5)P$_3$/AKT signaling has a role to control the activity of mTORC1 (48). However, we show that PTEN loss and AKT activation alone is not sufficient to activate mTORC1 in T cells. The molecular basis for the inability of PTEN deletion alone to drive mTORC1 activity is that PTEN deletion alone is not sufficient to induce the transport of nutrients such as glucose, glutamine and leucine that are essential for mTORC1 activity. In the context of System L transporter expression, leucine transport and mTORC1 activity in T-ALL cells the present studies identify NOTCH as a key driver. The engagement of T cells with NOTCH ligands is thus sufficient to induce leucine transport in T cells. Moreover the loss of NOTCH signaling in established T-ALL cells results in loss of leucine transporters and a failure to sustain mTORC1 activity. Previous studies have shown the importance of NOTCH control of c-Myc (14,15). The NOTCH control of amino acid transport shown herein reveals a mechanism that allows NOTCH to co-ordinate the c-Myc and also mTORC1 controlled metabolic pathways that are essential for T cell tumors (**summary Fig.5i**). These data reinforce previous ideas that pharmacological blockade of System L transport would be a valuable strategy to supress leukemia growth (26).

References

1.   Fox CJ, Hammerman PS, Thompson CB. Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol. 2005 Nov;5(11):844–52.

2.   Maciver NJ, Jacobs SR, Wieman HL, Wofford JA, Coloff JL, Rathmell JC. Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival. J Leukoc Biol. 2008 Oct;84(4):949–57.

3.   Macintyre AN, Finlay D, Preston G, Sinclair LV, Waugh CM, Tamas P, et al. Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. Immunity. 2011 Feb 25;34(2):224–36.

4.   Finlay DK, Rosenzweig E, Sinclair LV, Feijoo Carnero C, Hukelmann JL, Rolf J, et al. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J Exp Med. 2012 Dec 17;209(13):2441–53.

5.   Akers LJ, Fang W, Levy AG, Franklin AR, Huang P, Zweidler-McKay PA. Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combonation with rapamycin. Leukemia Res. 2011 Jun 1;35(6):814–20.

6.   Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med. 1992 Mar;33(3):325–9.

7.   Kishton RJ, Barnes CE, Nichols AG, Cohen S, Gerriets VA, Siska PJ, et al. AMPK is essential to balance glycolysis and mitochondrial metabolism to control T-ALL cell stress and survival. Cell Metabolism. 2016 Apr 12;23(4):649–62.

8.   Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity. 2011 Dec 23;35(6):871–82.

9.   Hukelmann JL, Anderson KE, Sinclair LV, Grzes KM, Murillo AB, Hawkins PT, et al. The cytotoxic T cell proteome and its shaping by the kinase mTOR. Nat Immunol. 2016 Jan;17(1):104-12.

10.   Weng AP, Ferrando AA, Lee W, Morris JP4, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004 Oct 8;306(5694):269–71.

11.   Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M, et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest. 2008 Nov 3;118(11):3762–74.

12.   Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y, et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood. 2009 Jul 16;114(3):647–50.

13.   Zhang J, Xiao Y, Guo Y, Breslin P, Zhang S, Wei W, et al. Differential requirements

for c-Myc in chronic hematopoietic hyperplasia and acute hematopoietic malignancies in Pten-null mice. Leukemia. 2011 Dec;25(12):1857–68.

14. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261–6.

15. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 2006 Aug 1;20(15):2096–109.

16. Yilmaz ÖH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature. 2006 Apr 5;441(7092):475–82.

17. Evangelisti C, Ricci F, Tazzari P, Tabellini G, Battistelli M, Falcieri E, et al. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia. 2011 May;25(5):781–91.

18. Kalaitzidis D, Sykes SM, Wang Z, Punt N, Tang Y, Ragu C, et al. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell. 2012 Sep 7;11(3):429–39.

19. Wang Y, Liu Y, Malek SN, Zheng P, Liu Y. Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell. 2011 Apr 8;8(4):399–411.

20. Giambra V, Jenkins C, Lam SH, Hoofd C, Belmonte M, Wang X, et al. Leukemia stem cells in T-ALL require active Hif1α and Wnt signaling. Blood. 2015 Jun 18;125(25):3917-27.

21. Sinclair LV, Rolf J, Emslie E, Shi Y-B, Taylor PM, Cantrell DA. Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat Immunol. 2013 May;14(5):500–8.

22. Shimobayashi M, Hall MN. Multiple amino acid sensing inputs to mTORC1. Cell Res. 2016 Jan;26(1):7–20.

23. Preston GC, Sinclair LV, Kaskar A, Hukelmann JL, Navarro MN, Ferrero I, et al. Single cell tuning of Myc expression by antigen receptor signal strength and interleukin-2 in T lymphocytes. EMBO J. 2015 Aug 4;34(15):2008-24.

24. Lindsten T, June CH, Thompson CB, Leiden JM. Regulation of 4F2 heavy-chain gene expression during normal human T-cell activation can be mediated by multiple distinct molecular mechanisms. Mol and Cell Biol. 1988 Sep;8(9):3820–6.

25. Finlay DK, Sinclair LV, Feijoo C, Waugh CM, Hagenbeek TJ, Spits H, et al. Phosphoinositide-dependent kinase 1 controls migration and malignant transformation but not cell growth and proliferation in PTEN-null lymphocytes. Journal of Experimental Medicine. 2009 Oct 26;206(11):2441–54.

26. Rosilio C, Nebout M, Imbert V, Griessinger E, Neffati Z, Benadiba J, et al. L-type

amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia. Leukemia. 2015 Jun;29(6):1253-66.

27.   Suzuki A, Yamaguchi MT, Ohteki T, Sasaki T, Kaisho T, Kimura Y, et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity. 2001 May;14(5):523–34.

28.   Hagenbeek TJ, Spits H. T-cell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus. Leukemia. 2008 Mar;22(3):608–19.

29.   Hagenbeek TJ, Wu X, Choy L, Sanchez-Irizarry C, Seshagiri S, Stinson J, et al. Murine Pten(-/-) T-ALL requires non-redundant PI3K/mTOR and DLL4/Notch1 signals for maintenance and γc/TCR signals for thymic exit. Cancer Letters. Cancer Lett. 2014 May 1;346(2):237–48.

30.   Waugh C, Sinclair L, Finlay D, Bayascas JR, Cantrell D. Phosphoinositide (3,4,5)-triphosphate binding to phosphoinositide-dependent kinase 1 regulates a protein kinase B/Akt signaling threshold that dictates T-cell migration, not proliferation. Mol Cell Biol. 2009 Nov;29(21):5952–62.

31.   Schmitt TM, de Pooter RF, Gronski MA, Cho SK, Ohashi PS, Zúñiga-Pflücker JC. Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. Nat Immunol. 2004 Apr;5(4):410–7.

32.   Hinton HJ, Clarke RG, Cantrell DA. Antigen receptor regulation of phosphoinositide-dependent kinase 1 pathways during thymocyte development. FEBS Lett. 2006 Oct 30;580(25):5845–50.

33.   Wieman HL, Wofford JA, Rathmell JC. Cytokine Stimulation Promotes Glucose Uptake via Phosphatidylinositol-3 Kinase/Akt Regulation of Glut1 Activity and Trafficking. Mol Biol Cell. 2007 Apr;18(4):1437-46.

34.   Hagenbeek TJ, Naspetti M, Malergue F, Garcon F, Nunes JA, Cleutjens KBJM, et al. The loss of PTEN allows TCR alphabeta lineage thymocytes to bypass IL-7 and Pre-TCR-mediated signaling. J Exp Med. 2004 Oct 4;200(7):883–94.

35.   Xue L, Nolla H, Suzuki A, Mak TW, Winoto A. Normal development is an integral part of tumorigenesis in T cell-specificPTEN-deficient mice. Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2022–7.

36.   Guo W, Schubbert S, Chen JY, Valamehr B, Mosessian S, Shi H, et al. Suppression of leukemia development caused by PTEN loss. Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1409–14.

37.   Shima EA, Le Beau MM, McKeithan TW, Minowada J, Showe LC, Mak TW, et al. Gene encoding the alpha chain of the T-cell receptor is moved immediately downstream of c-myc in a chromosomal 8;14 translocation in a cell line from a human T-cell leukemia. Proc Natl Acad Sci U S A. 1986 May;83(10):3439–43.

38.   Erikson J, Finger L, Sun L, ar-Rushdi A, Nishikura K, Minowada J, et al. Deregulation of c-myc by translocation of the alpha-locus of the T-cell receptor in T-cell leukemias.

Science. 1986 May;232(4752):884–6.

39. Laplante M, Sabatini DM. Regulation of mTORC1 and its impact on gene expression at a glance. J Cell Sci. 2013 Apr 15;126(Pt 8):1713–9.

40. Kaelin WGJ, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008 May 23;30(4):393–402.

41. Bar-Peled L, Sabatini DM. Regulation of mTORC1 by amino acids. Trends Cell Biol. 2014 Jul;24(7):400–6.

42. Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, Kanai Y. CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Arch. 2004 Feb;447(5):532–42.

43. Hoshii T, Tadokoro Y, Naka K, Ooshio T, Muraguchi T, Sugiyama N, et al. mTORC1 is essential for leukemia propagation but not stem cell self-renewal. J Clin Invest. 2012 Jun;122(6):2114–29.

44. Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood. 2007 Jul 1;110(1):278–86.

45. Swamy M, Pathak S, Grzes KM, Damerow S, Sinclair LV, van Aalten DMF, et al. Glucose and glutamine fuel protein O-GlcNAcylation to control T cell self-renewal and malignancy. Nat Immunol. 2016 Jun;17(6):712–20.

46. Zúñiga-Pflücker JC. Innovation: T-cell development made simple. NatRev Immunol. 2004 Jan;4(1):67–72.

47. Benadiba J, Rosilio C, Nebout M, Heimeroth V, Neffati Z, Popa A, et al. Iron chelation: an adjuvant therapy to target metabolism, growth and survival of murine PTEN-deficient T lymphoma and human T lymphoblastic leukemia/lymphoma. Leuk Lymphoma. 2016 Oct 13:1–13.

48. Dibble CC, Cantley LC. Regulation of mTORC1 by PI3K signaling. Trends Cell Biol. 2015 Sep;25(9):545-55.

Acknowledgements

Author contributions

K.M.G. designed and performed most of the experiments. M.S., E.E., J.L.H. and L.V.S. performed the experiments and provided intellectual input. D.A.C. designed the project and wrote the manuscript.

Conflict of interests

The authors declare no competing financial interests.

19

Figure legends

Figure 1. **PTEN$^{-/-}$ T-ALL cells upregulate nutrient transport**

Thymocytes isolated from *Pten*$^{fl/fl}$*Lck*-Cre^{-} or tumour bearing *Pten*$^{fl/fl}$*Lck*-Cre^{+} (T-ALL) mice were assayed for (**a**) ^{3}H-2-deoxyglucose and ^{3}H-glutamine uptake, (**b**) CD71 expression and APC-transferrin uptake, and (**c**) CD98 expression and ^{3}H-leucine uptake; ^{3}H-leucine uptake in cytotoxic T cells (CTL) is shown as a positive control. The glucose analogue 2-deoxyglucose was used to indicate glucose uptake. Representative nutrient uptake data shown include technical triplicate values, error bars indicate standard deviation. The data shown are representative of 3 biological replicates.

Figure 2. PTEN$^{-/-}$ non-transformed thymocytes have active AKT but do not upregulate nutrient uptake

Thymocytes were isolated from *Pten*$^{fl/fl}$*Lck*-Cre^{-}, *Pten*$^{fl/fl}$*Lck*-Cre^{+} and tumour-bearing *Pten*$^{fl/fl}$*Lck*-Cre^{+} (T-ALL) mice. (**a**) Immunoblots for phospho-AKT (T308) and (S473), phospho-PRAS40 (T246) and total AKT, PRAS40 and SMC1. Where indicated, cells were treated with Akti inhibitor (1μM, 1h), or pervanadate (100 μM, 10 min) to drive maximum AKT activity. (**b**) ^{3}H-2-deoxyglucose and ^{3}H-glutamine uptake from thymocytes of indicated genotypes. (**c**) Flow cytometry data of CD71 expression and APC-transferrin uptake. (**d**) CD98 expression and ^{3}H-leucine uptake from thymocytes of indicated genotypes. When indicated CTL were used as a positive control. The data shown are representative of (**a,c**) 3; (**b,d**) 4 biological replicates for each genotype.

Figure 3. Active mTORC1 controls HIF1α expression that is important for tumorigenesis in PTEN$^{-/-}$ TALL

20

(**a-d**) Thymocytes were isolated from $Pten^{\text{fl/fl}}Lck$-Cre$^-$, $Pten^{\text{fl/fl}}Lck$-Cre$^+$ and tumor-bearing $Pten^{\text{fl/fl}}Lck$-Cre$^+$ (T-ALL) mice. Immunoblots show (**a**) c-Myc and SMC1 expression, (**b**) phospho-S6K (T389), S6K and SMC1 expression. Thymocytes were treated as indicated with rapamycin (20nM, 1h), or phorbol ester (25ng/ml, 1h) as a positive control; (**c**) Whole proteome mass-spectrometry analysis of thymocytes isolated from 3 tumor bearing $Pten^{\text{fl/fl}}Lck$-Cre$^+$ (T-ALL) mice compared with thymocytes from 3 wild-type $Pten^{\text{fl/fl}}Lck$-Cre$^-$ mice. Shown is the fold change of estimated copy numbers of SREBP2 targets. (**d**) Immunoblot for HIF1α and SMC1 expression from thymocytes lysed directly after isolation (*ex vivo*) or cultured under 21% (normoxia) or 1% (hypoxia) of O_2 for 4h (left panel). Right panel: Densitometry analysis (ImageJ) of HIF1α expression in *ex vivo* isolated cells relative to loading control, each point is a biological replicate, n=4 for $Pten^{\text{fl/fl}}Lck$-Cre$^-$ and n=5 for $Pten^{\text{fl/fl}}Lck$-Cre$^+$, **$P < 0.01$ (t-test). (**e-h**) Immunoblot data from T-ALL cell lines F04 and F15 show (**e**) expression of phospho-S6K (T389), total S6K and SMC1 from cells treated rapamycin (20nM, 1h) or untreated; (**f**) shows expression of HIF1α, HIF1β, AKT and SMC1 from cells cultured in 21% (normoxia) or 1% (hypoxia) O_2 for 4h and (**g**) expression of HIF1α, phospho-S6K (T389), phospho-AKT (T308) and SMC1 and (**h**) c-MYC and SMC1 from cells +/- rapamycin (20nM) for indicated times. (**i**) ^{3}H-2-deoxyglucose uptake of F04 and F15 cells treated with or without rapamycin (20nM, 48h). (**j**) Thymocyte numbers from $Hif1a^{\text{wt/wt}}Lck$-Cre$^+$ and $Hif1a^{\text{fl/fl}}Lck$-Cre$^+$ mice, each point shown is a biological replicate, n=5. Total thymic cell number (left panel); thymocyte progenitor populations (right panel). NS-not significant (t-test). (**k**) Kaplan-Meier survival plot comparing kinetics of tumor development in $Pten^{\text{fl/fl}}Lck$-Cre$^+$ (n=34) mice with $Pten^{\text{fl/fl}}Hif1a^{\text{fl/fl}}Lck$-Cre$^+$ (n=41) mice. P-value was calculated by Log rank (Mantel-Cox) test. (**l**) ^{3}H-2-deoxyglucose uptake from *ex vivo* isolated $Pten^{\text{fl/fl}}Hif1a^{\text{fl/fl}}Lck$-Cre$^-$ and $Pten^{\text{fl/fl}}Hif1a^{\text{fl/fl}}Lck$-Cre$^+$ T-ALL cells. The data

21

shown are representative of (**a,b**) 5 and (**k**) 3 biological replicates for each genotype. The data shown in (**e-i**) are representative of 4 independent experiments.

Figure 4. Leucine transporter SLC7A5 is crucial for mTORC1 activity and tumorigenesis in PTEN[-/-] T-ALL cells

(**a**) Flow cytometry of phospho-S6 (S235/236) expression in murine F04 T-ALL cells maintained in complete RPMI +/- rapamycin (20nM) or RPMI lacking leucine or HBSS (no amino acids) for indicated times. The data are representative of 3 independent experiments. (**b**) Histograms showing the distribution of estimated copy numbers of individual proteins as measured by whole proteome mass-spectrometry from thymocytes isolated from 3 tumor bearing *Pten*[fl/fl]*Lck*-Cre[+] (T-ALL) mice. The estimated protein copy number of CD98, SLC7A6 and SLC7A5 are indicated. Protein copy number is quantified with the proteome ruler and presented as log- transformed mean values. (**c**) Kaplan-Meier survival plot comparing kinetics of tumor development in *Pten*[fl/fl]*Lck*-Cre[+] (n=18) mice compared with *Pten*[fl/fl]*Slc7a5*[fl/fl]*Lck*-Cre[+] (n=18) mice. P-value was calculated by Log rank (Mantel-Cox) test.

Figure 5. NOTCH signals are essential for maintenance of leucine transport in PTEN[-/-] T-ALL cells

(**a-c**) DN thymocytes isolated from wild-type mice were cultured on OP9 or OP9-DL1 in the presence of IL-7 (5 ng/ml, 48h) (**a**) ^{3}H-leucine uptake +/- System L transport inhibitor BCH (10mM), (**b**) CD98 expression and (**c**) intracellular phospho-S6 (S235/236) expression. (**d-h**) Murine T-ALL cell lines F04 and F15 were treated +/- DAPT (10μM) or rapamycin (20nM) for 48h; (**d**) immunoblot data showing expression of intracellular NOTCH1 (V1744), c-Myc, phospho-S6K (T389), HIF1α, phospho-AKT (T308), AKT and SMC1, (**e**) ^{3}H-leucine uptake

+/- BCH (10mM), (**f**) ^{3}H-2-deoxyglucose uptake. (**g**) Relative mRNA expression of *Slc7a5* and (**h**) relative mRNA expression of *Cd98*. mRNA levels were normalized to *Cd45*, *$P <$ 0.05, **$P <$ 0.01, ***$P <$ 0.001 (one-way ANOVA). (**i**) Schematic diagram of changes observed in non-transformed thymocytes from *Pten*$^{fl/fl}$*Lck*-Cre$^+$ and T-ALL cells from tumor berung *Pten*$^{fl/fl}$*Lck*-Cre$^+$ mice. PTEN$^{-/-}$ non-transformed thymocytes have low levels of mTORC1 activity and do not express c-Myc, HIF1α or NOTCH1. They also have low levels of nutrient transport. Malignant transformation leads to formation of PTEN$^{-/-}$ TALL that have high levels of mTORC1 activity and express HIF1α, NOTCH1 and c-Myc. They also have increased nutrient transport. Active NOTCH1 drives expression of System L transporters and as a consequence leucine transport. Leucine uptake leads to an increase in mTORC1 activity. Active mTORC1 controls expression of HIF1α and glucose uptake in PTEN$^{-/-}$ TALL. Additionally, NOTCH1 controls expression of c-Myc, a potential alternative driver for glucose transport (8). c-Myc expression is also regulated by mTORC1. Expression of c-Myc can be important for increased transport of glutamine (8) and iron (23) in PTEN$^{-/-}$ TALL. The data shown are mean from 2 biological replicates, error bars standard deviation and representative of (**b,c**) 3 biological replicates, , (**d**) 4 independent experiments. (**e,f**) Each point depicts an independent experimental replicate (n=3) consisting of the mean of technical triplicates. (**g,h**) Each point depicts an independent experimental replicate, n=5.

Figure 1

a

^{3}H-2-deoxyglucose

^{3}H-glutamine

Molecules tracer/cell/min (x10^{4})

Molecules tracer/cell/min (x10^{4})

■ *Pten*$^{fl/fl}$*Lck*-Cre^{-}
□ *Pten*$^{fl/fl}$*Lck*-Cre^{+} T-ALL

b

Events (% of max)

CD71

Thy1

transferrin

Thy1

■ *Pten*$^{fl/fl}$*Lck*-Cre^{-}
□ *Pten*$^{fl/fl}$*Lck*-Cre^{+} T-ALL

c

Events (% of max)

CD98

Thy1

^{3}H-leucine

Molecules tracer/cell/min (x10^{4})

■ *Pten*$^{fl/fl}$*Lck*-Cre^{-}
□ *Pten*$^{fl/fl}$*Lck*-Cre^{+} T-ALL
⌐¬ CTL

Figure 2

a

	Pten^fl/fl Lck-Cre^−	Pten^fl/fl Lck-Cre^+	Pten^fl/fl Lck-Cre^+ T-ALL
AKTi	+	+	+
Pervanadate	+	+	+

- 50 — pAKT (T308)
- 50 — pAKT (S473)
- 50 — panAKT
- 37 — pPRAS40 (T246)
- 37 — panPRAS40
- 150 — SMC1

b

³H-2-deoxyglucose

Molecules tracer/cell/min (×10⁴)

³H-glutamine

Molecules tracer/cell/min (×10⁴)

- Pten^fl/fl Lck-Cre^−
- Pten^fl/fl Lck-Cre^+
- CTL

c

Events (% of max) — CD71 — Thy1
- Pten^fl/fl Lck-Cre^−
- Pten^fl/fl Lck-Cre^+

Events (% of max) — transferrin — Thy1
- Pten^fl/fl Lck-Cre^−
- Pten^fl/fl Lck-Cre^+
- CTL

d

Events (% of max) — CD98 — Thy1
- Pten^fl/fl Lck-Cre^−
- Pten^fl/fl Lck-Cre^+

³H-leucine

Molecules tracer/cell/min (×10⁴)
- Pten^fl/fl Lck-Cre^−
- Pten^fl/fl Lck-Cre^+
- CTL

Figure 3

Figure 4

a

time in: 5 min   15 min   30 min

RPMI without Leucine

HBSS (no amino acids)

RPMI with Rapamycin

Events (% of max)

pS6 (S235/236)

RPMI
RPMI without Leucine

RPMI
HBSS (no amino acids)

RPMI
RPMI with Rapamycin

b

$Pten^{fl/fl}Lck$-Cre$^+$ T-ALL

$Pten^{fl/fl}Lck$-Cre$^+$ T-ALL

$Pten^{fl/fl}Lck$-Cre$^+$ T-ALL

Proteins in bin (#)

SLC7A6   CD98   SLC7A5

SLC7A5   SLC7A6   CD98

SLC7A5   SLC7A6   CD98

Estimated copy numbers ($\log_{10}$)

c

Tumor free survival (%)

**** <0.0001

Time to morbidity (d)

$Pten^{fl/fl}Lck$-Cre$^+$
$Pten^{fl/fl}Slc7a5^{-/-}Lck$-Cre$^+$

Figure 5

a
³H-leucine

b
CD98
- OP9
- OP9 DL1

c
pS6 (S235/236)
- OP9
- OP9 DL1

d

DAPT	F04	F15
Rapamycin	+	+

- IC NOTCH1 (V1447)
- c-Myc
- pS6K (T389)
- HIF1α
- pAKT (T308)
- panAKT
- panS6K

e
³H-leucine

f
³H-2-deoxyglucose

g
Slc7a5 mRNA (normalized to CD45)

h
Cd98 mRNA (normalized to CD45)

i

BEFORE TRANSFORMATION

low mTORC1 · PTEN⁻/⁻ · c-Myc · Hif1α · NOTCH1

AFTER TRANSFORMATION

PTEN⁻/⁻ TALL → NOTCH1

NOTCH1 → SYSTEM L EXPRESSION → LEUCINE TRANSPORT → mTORC1 activity → Hif1α → GLUCOSE TRANSPORT

NOTCH1 → c-Myc → GLUTAMINE and IRON TRANSPORT

nutrient transport
lo — hi